Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Maximum cumulative doses of antineoplastic drugs
- At: 2018 FIP Congress in Glasgow (Scotland)
- Type: Poster
- By: MORGADO, Manuel (University of Beira Interior, Health Science Faculty)
- Co-author(s): Carolina Gouveia: Health Science Faculty, University of Beira Interior, Covilhã, Portugal
Telma Vicente: Health Science Faculty, University of Beira Interior, Covilhã, Portugal
Ema Paulino: Portuguese Pharmaceutical Society, Lisbon, Portugal
Manuel Morgado: Health Science Faculty, University of Beira Interior, Covilhã, Portugal;Higher School of Health, Polytechnic Institute of Guarda, Guarda, Portugal;Pharmaceutical Services, Hospital Centre of Cova da Beira, Covilhã, Portugal
BackgroundAntineoplastic drugs are increasingly used in malignant diseases. These drugs are not completely selective for tumor cells, which limits the dose that can be used. For that reason, cytotoxic drugs administration is commonly limited to a cumulative safe dose.
MethodsThe Summary of Product Characteristics of each cytotoxic available in.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019